<DOC>
	<DOCNO>NCT01647542</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety TAK-875 Asia Pacific adult type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Daily Oral TAK-875 25 50mg Asia Pacific Adults With Type 2 Diabetes</brief_title>
	<detailed_description>The drug test study call TAK-875 . TAK-875 test treat people diabetes . The study enroll approximately 750 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - TAK-875 25 mg daily - TAK-875 50 mg daily - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient All participants ask take one tablet time day throughout study . All participant ask record time low blood sugar symptom diary . This multi-centre trial conduct Asia Pacific region . The overall time participate study 30 week . Participants make 13 visit clinic . Due potential concern liver safety , balance , benefit treat patient fasiglifam ( TAK-875 ) outweigh potential risk . For reason , Takeda decide voluntarily terminate development activity fasiglifam .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . In opinion investigator , patient capable understanding comply protocol requirement . 2 . The patient , applicable , patient 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Male female , age least 18 year legal age consent country great 18 year , historical diagnosis T2DM . 4 . Has HbA1c 7.0 % 10.0 % , inclusive screening , treat diet exercise least 3 month . 5 . Has body mass index ( BMI ) ≤45 kg/m^2 screening . 6 . Patients regularly use , nonexcluded medication , must stable dose least 4 week prior Screening . However , PRN ( need ) use prescription overthecounter medication allow discretion investigator . 7 . A female childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent throughout duration study 30 day last dose study drug . 8 . Is able willing monitor glucose home glucose monitor consistently record blood glucose concentration complete subject diary . 1 . Is unable understand official language ( verbal write ) country certify translation approve informed consent available . 2 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ; biological legally adopt ) may consent duress . 3 . Has hemoglobin level ≤12 g/dL ( ≤120 g/L ) ( male ) ≤10 g/dL ( ≤100 g/L ) ( female ) Screening Visit . 4 . Has history hemoglobinopathy may affect determination HbA1c . 5 . Donated receive blood product within 12 week prior Screening plan donate blood study . 6 . Has systolic blood pressure ≥160 mm Hg diastolic pressure ≥95 mm Hg Screening Baseline ( If patient meet exclusion criterion , assessment may repeat least 30 minute initial measurement decision make base second measurement ) . 7 . Had coronary angioplasty , coronary stent placement , coronary bypass surgery , myocardial infarction , unstable angina pectoris , clinically significant abnormal electrocardiogram , cerebrovascular accident transient ischemic attack within 3 month prior Screening . 8 . Has serum creatinine level ≥1.5 mg/dL ( male ) ≥1.4 mg/dL ( female ) and/or estimate glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73m^2 Screening . 9 . Has uncontrolled thyroid disease . 10 . Has history laser treatment proliferative diabetic retinopathy within 6 month prior Screening . 11 . Has history treatment diabetic gastric paresis , gastric banding , gastric bypass surgery . 12 . Has alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) level &gt; 2.0x upper limit normal range ( ULN ) Screening . 13 . Has total bilirubin level great ULN Screening . Exception : patient document Gilbert 's Syndrome , allow elevated bilirubin level per investigator 's discretion . 14 . Has know history infection human immunodeficiency virus ( HIV ) , Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) . 15 . If patient know history HBV infection , HBV Screening test panel do . If test positive clinical manifestation active infection per Investigator 's diagnosis , patient exclude . In addition , patient consider need antiviral treatment , patient exclude . ( If test result indicate hepatitis B surface antigen ( HBsAg ) carrier without clinical manifestation active infection , antiviral treatment need , patient could enrol provide criterion meet . ) 16 . Has history cancer remission &lt; 5 year prior Screening . A history basal cell carcinoma stage 1 squamous cell carcinoma skin allow . 17 . Has receive investigational compound within 30 day prior Screening receive &gt; 7 day antidiabetic agent within 3 month prior Screening . 18 . Has receive TAK875 previous clinical study . 19 . Has history hypersensitivity , allergies anaphylactic reaction ( ) component TAK875 . 20 . Has history drug abuse ( define illicit drug use ) history alcohol abuse ( define regular daily consumption 4 alcoholic drink per day ) within 2 year prior Screening . 21 . Received excluded medication prior Screening expect receive exclude medication . 22 . If female , pregnant ( confirmed laboratory testing , ie , serum/urine human chorionic gonadotropin ( hCG ) , females childbearing potential ) lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 23 . If male , intend donate sperm course study 30 day final study medication dose . 24 . Has physical psychiatric disease condition judgment investigator may affect life expectancy may make difficult successfully manage follow subject accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>